Corneal collagen cross-linking (CCL) therapy is primarily applied to halt the progression of various corneal ectatic diseases, particularly keratoconus. This treatment offers an effective option for pellucid marginal degeneration (PMD), a variant of keratoconus, and especially for iatrogenic ectasias that develop after Excimer Laser surgery. Furthermore, in patients with insufficient corneal thickness, CCL and Excimer Laser can be combined, either before or concurrently with Excimer Laser treatment, to minimize the risk of post-laser ectasia.